Viridian Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by Viridian Therapeutics, Inc. on June 8, 2022. The record date for voting was April 14, 2022, with 27,169,422 shares of common stock issued and outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on four proposals at the Annual Meeting:
- Election of Class I Director: Peter Harwin was elected with 15,491,361 votes for, 114,534 votes withheld, and 4,675,151 broker non-votes.
- Ratification of Auditors: KPMG LLP was ratified as the independent registered public accounting firm for 2022 with 20,279,290 votes for, 1,305 against, and 451 abstentions.
- Executive Compensation (Say-on-Pay): Approved on an advisory basis with 13,209,757 votes for, 2,389,695 against, 6,443 abstentions, and 4,675,151 broker non-votes.
- Equity Incentive Plan Amendment: Approved an amendment to the 2016 Equity Incentive Plan, including an increase of 3,050,000 shares reserved for issuance. The vote was 13,142,519 for, 2,299,758 against, 163,618 abstentions, and 4,675,151 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the impact of the approved 3,050,000 share increase in the Equity Incentive Plan on potential future dilution.
- Note the significant number of broker non-votes (4,675,151) on the director election, executive compensation, and equity plan proposals.
- Confirm the re-election of Peter Harwin to the Board of Directors.
- Review the full proxy statement for detailed executive compensation data referenced in the advisory vote.